Abstract
Individual genetic variation can have a major impact on the clinical manifestation of a movement disorder and its response to treatment. Advances in gene discovery and increasing availability of diagnostic genetic testing have led to the identification of a growing number of patients with well-defined hereditary movement disorders. Establishing a genetic diagnosis may greatly impact patient counseling and shape therapeutic decisions. Further, assignment of a movement disorder to a specific genetic defect holds promise for the development of causal treatment approaches and individualized therapies, especially as the first gene-targeted approaches have recently entered clinical trials. However, important gaps remain, that is, genetic testing results are often inconclusive, gene-specific treatment options are still exceedingly rare, and designing clinical trials to demonstrate disease modification continues to pose a major challenge. © 2019 International Parkinson and Movement Disorder Society.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Movement Disorders |
| Jahrgang | 34 |
| Ausgabenummer | 9 |
| Seiten (von - bis) | 1294-1299 |
| Seitenumfang | 6 |
| ISSN | 0885-3185 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 01.09.2019 |
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
-
SDG 10 – Weniger Ungleichheiten
Strategische Forschungsbereiche und Zentren
- Querschnittsbereich: Medizinische Genetik
Fingerprint
Untersuchen Sie die Forschungsthemen von „Will genotype drive treatment options?“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver